Table 1 Incidence of ocular morbidity after completion of 2 year fixed MDT, by patient.
| Ocular conditions | Person time at risk (years) | Number of patients at risk* | Number of cases | Incidence rate per 100 person years | 95% CI |
|---|---|---|---|---|---|
| Lid conditions | |||||
| Orbicularis weakness | 2033 | 256 | 11 | 0.54 | (0.30 to 0.98) |
| Lagophthalmos | 2106 | 262 | 5 | 0.24 | (0.10 to 0.57) |
| Ectropion | 2186 | 271 | 4 | 0.18 | (0.07 to 0.49) |
| Trichiasis | 2163 | 272 | 14 | 0.65 | (0.38 to 1.09) |
| Conjunctival conditions | |||||
| B663 crystals† | 2203 | 273 | 2 | 0.09 | (0.02 to 0.36) |
| NLD‡ | 2139 | 270 | 12 | 0.56 | (0.32 to 0.99) |
| Pterygium | 1839 | 231 | 13 | 0.71 | (0.41 to 1.22) |
| Corneal conditions | |||||
| Corneal opacity | 1420 | 221 | 76 | 5.35 | (4.27 to 6.70) |
| Punctate keratitis¶ | 2057 | 267 | 21 | 1.02 | (0.66 to 1.57) |
| Corneal ulcer | 2229 | 278 | 3 | 0.13 | (0.04 to 0.42) |
| Corneal nerve beading | 2006 | 260 | 19 | 0.95 | (0.60 to 1.48) |
| Uveal conditions | |||||
| Keratic precipitates | 1886 | 249 | 20 | 1.06 | (0.68 to 1.64) |
| Flare and/or cells | 2198 | 274 | 5 | 0.23 | (0.09 to 0.55) |
| Iris atrophy | 2005 | 263 | 60 | 2.99 | (2.32 to 3.85) |
| Uveal involvement, total§ | 1692 | 236 | 64 | 3.78 | (2.96 to 4.83) |
| Episcleritis | 2224 | 277 | 4 | 0.18 | (0.07 to 0.48) |
| Cataract | |||||
| Cataract | 1293 | 179 | 54 | 4.18 | (3.20 to 5.45) |
| Cataract and visual acuity ⩽6/18 | 1706 | 229 | 41 | 2.40 | (1.77 to 3.26) |
| Grouped | |||||
| LROP | 1326 | 202 | 75 | 5.65 | (4.51 to 7.09) |
| PBLROP 1608 | 225 | 62 | 3.86 | (3.01 to 4.95) | |
MDT, multidrug therapy; LROP, leprosy related ocular pathology includes muscle weakness, lagophthalmos, ectropion, entropion, trichiasis, episcleritis, scleritis, corneal nerve beading, punctate keratitis and uveal involvement. PBLROP, potentially blinding leprosy related ocular pathology includes lagophthalmos and/or uveal involvement.
*The number of patients at risk for each event is based on the number of patients who were event free at the completion of MDT and who had at least one follow up examination visit thereafter. †B663 crystals, clofazamine crystals in cornea or conjuctiva; ‡Nasolacrimal duct patency; ¶Neurotrophic or exposure related. §Any uveal involvement includes flare and cell, keratic precipitates, and/or iris atrophy. Corneal opacities were not included, because none of them was vision threatening.